Howell discusses the crucial role health care providers, particularly ophthalmologists, can play in reducing health disparities for patients with diabetic macular edema (DME). Referring to a study by Julia Haller, MD, Howell outlines 3 key aspects for addressing disparities.

Firstly, Haller’s study emphasizes the significance of clinical trial enrollment in patients with DME. Disparities are evident in underrepresented groups, such as Black, Hispanic, and Asian patients, with lower enrollment compared to White patients. This underrepresentation leads to a lack of data on clinical health outcomes for minority groups, hindering improvements and widening health disparities.

Secondly, real-world data analysis from the Medicare population reveals significant disparities in DME treatment. Black, Hispanic, and Asian patients are 70% to 80% less likely to be treated for DME compared to their White counterparts. Moreover, those treated in these groups are more likely to receive less effective off-label treatments, such as laser photo coagulation.

Lastly, the study highlights disparities in the initiation of timely treatment for newly diagnosed DME patients. Black, Asian, and female patients, along with certain age groups, are less likely to receive prompt treatment, leading to preventable visual outcome disparities. Howell emphasizes the importance of timely identification, diagnosis, and initiation of treatment, particularly with anti–vascular endothelial growth factor injections for underrepresented groups.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.